These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36861804)

  • 1. Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review.
    Nema P; Asati V; Kendya P; Gupta T; Agarwal S; Kori S; Kashaw V; Iyer AK; Kashaw SK
    Mini Rev Med Chem; 2023; 23(21):2008-2040. PubMed ID: 36861804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
    Li H; Fang Y; Guo S; Yang Z
    Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
    [No Abstract]   [Full Text] [Related]  

  • 3. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T; Yoshida S
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
    Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
    Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
    Shah U; Kowalski TJ
    Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
    Fyfe MC; McCormack JG; Overton HA; Procter MJ; Reynet C
    Expert Opin Drug Discov; 2008 Apr; 3(4):403-13. PubMed ID: 23489096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
    Nunez DJ; Bush MA; Collins DA; McMullen SL; Gillmor D; Apseloff G; Atiee G; Corsino L; Morrow L; Feldman PL
    PLoS One; 2014; 9(4):e92494. PubMed ID: 24699248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus.
    Manaithiya A; Alam O; Sharma V; Javed Naim M; Mittal S; Khan IA
    Bioorg Chem; 2021 Aug; 113():104998. PubMed ID: 34048996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia.
    Li NX; Brown S; Kowalski T; Wu M; Yang L; Dai G; Petrov A; Ding Y; Dlugos T; Wood HB; Wang L; Erion M; Sherwin R; Kelley DE
    Diabetes; 2018 Jul; 67(7):1401-1413. PubMed ID: 29669745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
    Overton HA; Fyfe MC; Reynet C
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chylomicrons stimulate incretin secretion in mouse and human cells.
    Psichas A; Larraufie PF; Goldspink DA; Gribble FM; Reimann F
    Diabetologia; 2017 Dec; 60(12):2475-2485. PubMed ID: 28866808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms.
    Flock G; Holland D; Seino Y; Drucker DJ
    Endocrinology; 2011 Feb; 152(2):374-83. PubMed ID: 21068156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion.
    Chepurny OG; Holz GG; Roe MW; Leech CA
    Mol Endocrinol; 2016 Jun; 30(6):614-29. PubMed ID: 27082897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways.
    Lan H; Lin HV; Wang CF; Wright MJ; Xu S; Kang L; Juhl K; Hedrick JA; Kowalski TJ
    Br J Pharmacol; 2012 Apr; 165(8):2799-807. PubMed ID: 22029751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of GPR119 agonists as a future treatment for type 2 diabetes.
    Dhayal S; Morgan NG
    Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal hormonal responses on GPR119 activation in lean and diseased rodent models of type 2 diabetes.
    Patel S; Mace OJ; Tough IR; White J; Cock TA; Warpman Berglund U; Schindler M; Cox HM
    Int J Obes (Lond); 2014 Oct; 38(10):1365-73. PubMed ID: 24451185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin hormones and type 2 diabetes.
    Nauck MA; Müller TD
    Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.